What Newrotex Ltd does

Newrotex Limited is a privately-held UK biotech company founded in 2019 and headquartered at the Wood Centre for Innovation in Oxford. The company is developing silk-based peripheral nerve repair medical devices, with its core technology platform centred on SilkAxons™ — bundles of luminal spider silk fibres harvested from Nephila spiders that act as a scaffold mimicking natural Bands of Büngner to guide axonal regeneration. SilkAxons™ is designed for use either implanted inside a harvested vein or pre-loaded into the Oxford Nerve Conduit, an off-the-shelf porous silk sheath. The 10cm implant targets large-gap peripheral nerve injuries (>5cm) where current FDA-approved devices and hollow conduits fail, and where autografts (the current standard of care) require a second surgical site, long operating times, and yield ≤50% recovery with significant complication risk.

The company holds patented silk-based technology and uses a Spidrex silk platform licensed from Oxford Biomaterials (co-founded by Founder-Director Prof Fritz Vollrath, who leads the Oxford Silk Group at the University of Oxford). Manufacturing is conducted at ISO 13485-certified facilities in Oxford. Newrotex is pre-revenue and entered first-in-human clinical trials in August 2025 at The Panama Clinic with bioaccess® as CRO partner, having secured Panama regulatory approval in July 2025 just two weeks after ethics submission. Preliminary safety data is expected Q1 2026, after which the company plans a pivotal study supporting FDA (US) and MHRA (UK) market approval filings.

The commercial model is enterprise hospital-direct sales of an off-the-shelf, room-temperature-storable medical device targeting surgeons across trauma, orthopaedics, plastic surgery, oncology, breast reconstruction, OMFS, and urology. Revenue is expected to derive from one-time device sales to hospitals and surgical centres, with future platform applications (organoids for CNS drug testing, drug/growth factor delivery, CNS/spinal cord repair) potentially monetised via licensing or co-development. Pricing is undisclosed but positioned as low-cost relative to autograft procedures. The company is grant-funded (£2.5M cumulative Innovate UK) and Knowledge-Intensive EIS eligible, with a ~10-person team led by Founder-CEO Dr Alex Woods and Chairman Chris Jones (Becton Dickinson Director).

Name

Newrotex Ltd

Legal name

Newrotex Limited

Website

https://newrotex.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Newrotex Limited is a UK-based, pre-revenue biotech developing silk-based peripheral nerve repair devices — SilkAxons™ and the Oxford Nerve Conduit — for large-gap (up to 10cm) peripheral nerve injuries. The company targets hospital procurement across multiple surgical specialties and is currently in first-in-human trials.

Ownership category

akta.pro rank

Product category

Peripheral Nerve Repair Medical Devices

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

akta.pro secondary industry

Neural & Spinal Cord Regeneration (HLAAAGAI)

Keywords

• Peripheral nerve repair
• Silk biomaterials medical devices
• Nerve regeneration implants
• Biodegradable surgical conduits
• Regenerative medicine devices

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. SilkAxons™ Nerve Guide (Medical Device Sales): Newrotex is developing silk-based nerve repair medical devices (SilkAxons™ luminal fibres and Oxford Nerve Conduit) intended for commercial sale to hospitals and surgical centres upon regulatory approval. The company is in first-in-human clinical trials with safety data expected Q1 2026, followed by market approval studies in the USA and UK. Revenue will be generated through direct device sales to healthcare institutions.
2. Future Platform Licensing (Silk Technology): The company notes it is developing its silk platform technology for additional applications including organoids for pharmaceutical CNS testing, drug/growth factor delivery vehicles, and central nervous system (CNS) repair. These future verticals may be monetised through licensing agreements, co-development partnerships, or direct product sales.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

Newrotex develops and manufactures silk-based medical devices for peripheral nerve repair. Its core products are SilkAxons® — bundles of luminal spider silk fibres harvested from Nephila spiders for implantation in a vein or hollow conduit — and the Oxford Nerve Conduit, an off-the-shelf silk-based peripheral nerve conduit pre-filled with SilkAxons® fibres. Together these provide a biodegradable, off-the-shelf scaffold for nerve re-growth that bridges gaps of up to 10cm and can be stored at room temperature.

Product overview

Newrotex develops silk-based medical solutions for the nervous system, with two main products: SilkAxons® (luminal spider silk fibres for implantation into veins or conduits) and the Oxford Nerve Conduit (off-the-shelf silk conduit pre-filled with SilkAxons®). Both products address peripheral nerve injuries, with SilkAxons® serving as the core technology platform that can be used standalone or within the conduit system.

Differentiator

Problem solved

Functional benefit

Products and services

• SilkAxons® A 10cm implant made from bundles of luminal spider silk fibres harvested from Nephila spiders that can be implanted into a vein or inserted into hollow conduits to support nerve re-growth. Designed for large peripheral nerve-gap repairs (up to 10cm, more than triple the reach of current FDA-approved devices), mimics natural Bands of Büngner, and has been shown in preclinical/early clinical work to support superior axonal regeneration comparable or superior to autografts.
• Oxford Nerve Conduit An off-the-shelf, pre-filled silk-based peripheral nerve conduit containing SilkAxons® luminal silk fibres, negating the need to thread the implant through a vein during surgery. Features a porous tubular biocompatible sheath designed to encourage vascularisation, providing surgical ease and wide accessibility for surgeons across multiple specialties performing peripheral nerve repair.

Quantifiable outcome

• Bridges nerve gaps up to 10cm, more than triple the reach of current FDA-approved devices
• +5 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Integra LifeSciences (AxoGen): Integra completed its acquisition of AxoGen in 2024, giving it the dominant peripheral nerve repair franchise (Avance processed nerve allograft, AcroVal, NeuraGen, NeuraWrap). Directly competes with Newrotex in large-gap PNI across trauma, plastic surgery, and OMFS.
• Polyganics: Netherlands-based medical device company commercialising Neurolac nerve cap and Neurolac nerve conduit for peripheral nerve repair. Targets the same hollow-conduit segment of the PNI market as Newrotex's SilkAxons and Oxford Nerve Conduit.

Broad incumbents

• Baxter International (Synovis): Through its Synovis portfolio, Baxter markets nerve repair and reconstruction products to surgeons globally. A broader medical device incumbent with overlapping channels in trauma and reconstructive surgery.
• Stryker: Large orthopaedic and surgical device company with nerve repair and ENT/neuro surgery adjacencies. Competes for hospital budgets and OR shelf space rather than head-to-head on biomaterial nerve conduits specifically.

Emerging players

• Checkpoint Surgical: US developer of intraoperative nerve stimulation and identification devices used during nerve repair surgery. A complementary adjacent technology rather than a direct conduit competitor, but shares surgeon customers and OR channels.
• Renerva: Pittsburgh-based early-stage company developing injectable biomaterial matrices to enhance peripheral nerve regeneration. A relevant emerging peer because it directly competes in the same PNI biological scaffold space as Newrotex.
• Orthocell: Australian regenerative medicine company developing nerve repair (Celgro nerve guidance) and orthobiologic products. Comparable as a small-cap, clinical-stage company commercialising a biological nerve repair technology outside the US market.

Regional players

• Medovate: UK-based medical device company accelerating NHS-focused surgical innovations, with products in adjacent surgical categories. Geographically and structurally comparable as a small UK medtech commercialising through the same hospital channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/newrotex-limited

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds8 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Newrotex Ltd